Ofatumumab Biosimilar - Research Grade

Target: CD20.

Specificity: Detects human CD20. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Ofatumumab.

Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background: Ofatumumab biosimilar is an IgG1κ human monoclonal antibody with a molecular weight of approximately 149 kDa. The antibody is produced in a recombinant CHO cell line using standard mammalian cell cultivation and purification technologies.

Concentration: 1.0 - 5.0 mg/ml.

Formulation: Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Purity: >95% by SDS-PAGE and HPLC.

Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.